New Strategies for Multiple Myeloma Care: Case Studies for Nurses – Part 1: Newly Diagnosed Multiple Myeloma
Release Date: August 18, 2020
Expiration Date: August 18, 2021
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity on newly diagnosed multiple myeloma will include an overview of the disease, as well as current treatment workup and testing recommendations for multiple myeloma. Through the cases of June and Lisa, our faculty will explore transplant eligibility, induction, and maintenance therapy. Please remember to complete part 2 and 3 to receive a total of 1.5 CNE credits (3 sessions at 0.5 CNE). Free downloadable tools and resources are provided after completing the post-test and activity evaluation survey.
This activity is designed for nurses and other medical personnel involved in care of patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Identify common treatment regimens in newly diagnosed and relapsed multiple myeloma
- Discuss nursing management of MM patients receiving myeloma therapeutic regimens, including effective symptom management
- Discuss the importance of survivorship care plans and practical tools for long-term management and care of MM patients
- Discuss timely recommendations for infection control among an immunocompromised patient population
Newly Diagnosed Multiple Myeloma
- Common treatment regiments
- Recommendations for infection control
- Survivorship care plans and practical tools for long-term management and care
- Two case studies:
- June - an older newly diagnose patient
- Lisa - a younger transplant eligible newly diagnosed patient
Instructions for Participation and Credit
This activity is eligible for credit through August 18, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You will be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 100%. You will be able to review the correct answers along with the rationale before completing the program. Please note you must achieve a passing score within 3 attempts or you will be unable to complete the activity and earn CNE credit.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.
- Your online certificate will be saved on ManagingMyeloma.com in your CE Records, which you can access at any time using your login.
Adult Nurse Practitioner
Multiple Myeloma Program
Cleveland Clinic Taussig Cancer Institute
Dr. Beth Faiman received a Bachelor of Science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996. She received a Master of Science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002 and a PhD in Clinical Research and Nursing from Case Western Reserve University in 2014. Dr. Faiman holds an advanced oncology nurse certification through ONCC. She is currently employed as an Adult Nurse Practitioner in the department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic in Cleveland, Ohio. She is adjunct faculty at Ursuline College, Case Western Reserve University, and Kent State University. Dr. Faiman is the recipient of a many awards including the 2012 Excellence in Medical Oncology, the 2013 Commendation for Patient and Nursing Education Award sponsored by The Oncology Nursing Society, and the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University. She was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016. Additionally, Dr. Faiman was recognized by ONS for her contributions to healthcare through selection to the American Academy of Nursing in 2019, and the American Board of Internal Medicine (ABIM) appointed Dr. Beth Faiman to ABIM Hematology Specialty Board in July. The ABIM is responsible for governing the licensure of current and future board-certified hem/onc physicians.
Dr. Faiman is an active author, presenter, and educator on the topics of multiple myeloma, amyloidosis, chronic leukemia, plasma cell dyscrasias, and general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is currently Editor-in-Chief of The Oncology Nurse APN/PA and on the editorial board of ASH Clinical News among others. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of multiple myeloma, treatment adherence, pain, palliation, and cancer symptom management. Dr. Faiman has served as a prolific speaker, publisher, and committee leader conducting original research for over thirteen years as a distinguished member of the International Myeloma Foundation Nurse Leadership Board.
Assistant Professor, School of Nursing
Associate Co-Director DNP Program
College of Science and Health
De Paul University
Dr. Tariman is a Fellow in the American Academy of Nursing and active member of Oncology Nursing Society, Midwestern Nursing Research Society, American Society of Hematology, Nursing Organization of Nurse Practitioner Faculty, PNAA-Illinois, and ANA-Illinois. He is the Immediate Past President and the Nominating Chair for the 800+ members of the Chicago Chapter of the Oncology Nursing Society.
Dr. Joseph Tariman is a graduate of the PhD in Nursing Science Program at University of Washington. He obtained his Bachelor of Science in Nursing, and Master of Arts in Nursing in Cebu, Philippines in 1991 and 1993, respectively. He completed a post-master’s certificate program in Adult Health Nurse Practitioner at the University of Miami-Coral Gables in 2001. He worked as the lead nurse practitioner from 2002-2006 and 2010-2014 at Northwestern University Myeloma Program in Chicago, IL and served as a key research personnel for all phase 1 and 2 clinical therapeutic trials for myeloma. Dr. Tariman has developed and validated the only measure that is designed to assess the knowledge, attitudes, and adaptability and communication skills of oncology nurse clinicians on Shared Decision Making (SDM). He is currently the Associate Co-Director for the DNP Program at De Paul University.
Dr. Tariman has served on numerous editorial and review boards such as Oncology Nursing Forum, Clinical Journal of Oncology Nursing, Western Journal of Nursing Research, The Oncology Nurse, Journal of the Advanced Practitioner in Oncology, Psycho-Oncology, Journal of Nursing Practice Applications and Review of Research, ONS Connect, and Advance for Nurse Practitioners. He is the recipient of numerous awards including two outstanding alumni awards: the 2016 UVCN Excellence in Nursing Practice Research and Education Award and the 2018 CDU Most Outstanding Alumni Awards for Graduate School. He also received the 2011 Honored Nurse of the Year Award from the Chicago Leukemia & Lymphoma Society, the 2012 Nurse of the Year Award from Leukemia Research Foundation, and the 2013 ONS Publisher’s Outstanding Achievement for Oncology Nursing Education or Family/Patient Education. Dr. Tariman serves on an advisory board for the Oncology Nursing Society Foundation. Dr. Tariman is an esteemed member of the International Myeloma Foundation Nurse Leadership Board and has served on the board since its inception in 2006.
|Nursing Continuing Education
Accreditation Statement: Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement: 0.5 contact hours may be earned for successful completion of this activity. A total of 1.5 contact hours may be earned by completing all 3 activities in this course.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CNE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CNE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Name of Faculty
Reported Financial Relationship
|Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN||
Consulting fee from Celgene/BMS, GSK, Karyopharm
|Joseph D. Tariman, PhD, RN, ANP-BC, FAAN||
None to disclose
The content and program managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Content or Program Manager
Reported Financial Relationship
Annenberg Center for Health Sciences at Eisenhower
None to disclose
Joyce Divine, PhD, MBA
Employment by the Lockwood Group
Michelle Faber, MS
None to disclose
Diane Moran, RN, MA, EdM
None to disclose
Maya Ormsby, MS, MBA, MIM
None to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
A presentation timeslot has been assigned to provide a symposium supported by the International Myeloma Foundation during the Oncology Nursing Society’s (ONS) Bridge Virtual Event. The Oncology Nursing Society's assignment of a presentation timeslot does not imply product endorsement.
Provided by the International Myeloma Foundation
Accredited by Annenberg Center for Health Sciences at Eisenhower
Supported by educational grants from Bristol Myers Squibb (formerly Celgene); GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; Oncopeptides, Inc.; Sanofi Genzyme; and Takeda Oncology.
©2020 International Myeloma Foundation, 12650 Riverside Drive, Suite 206, North Hollywood, CA 91607, USA, Tel: 1-818-487-7455
No portion of this material may be copied or duplicated without the expressed permission of the International Myeloma Foundation.